减少儿科重症监护病房经验性万古霉素使用:一项多中心研究
这项多中心中断时间序列研究纳入美国3家儿童医院的5个PICU,评估以共识指南、教育和组级审计反馈为核心的多层面管理干预对减少经验性万古霉素使用的影响。结果显示,干预后经验性万古霉素使用立即降低(OR 0.71,95%CI 0.54-0.95,P=0.02),经验性万古霉素天数减少24%(IRR 0.76,95%CI 0.65-0.89,P<0.01),且未增加死亡率、器官功能障碍或漏诊MRSA感染。
要点
- 多层面管理干预可立即减少PICU经验性万古霉素使用及治疗天数。
- 干预后未观察到死亡率、器官功能障碍或漏诊MRSA感染增加。
- 支持在PICU针对经验性抗生素处方开展管理干预的安全性和可行性。
核心结论
- 多层面管理干预减少了经验性万古霉素使用,且无伤害证据。
研究设计与样本
- 多中心中断时间序列研究,纳入美国3家儿童医院的5个PICU,干预针对4549次疑似严重细菌感染发作。
- 干预包括共识指南、教育和组级审计与反馈。
主要发现
- 干预后经验性万古霉素使用立即降低(OR 0.71,95%CI 0.54-0.95,P=0.02),干预后斜率无显著变化。
- 疑似严重细菌感染发作后经验性万古霉素天数立即减少24%(IRR 0.76,95%CI 0.65-0.89,P<0.01),干预后斜率无显著变化。
- 干预后死亡率、器官功能障碍或未覆盖的侵袭性MRSA感染均未增加。
临床怎么用
- 在PICU中可实施包含共识指南、教育和审计反馈的多层面管理干预以减少经验性万古霉素使用。
- 干预未见死亡率、器官功能障碍或漏诊MRSA感染增加,支持其安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vancomycin is frequently administered empirically for suspected serious bacterial infections (SBI) in the pediatric intensive care unit (PICU) despite low prevalence of methicillin-resistant Staphylococcus aureus (MRSA). METHODS: We performed a multicenter interrupted time series (ITS) study including five PICUs in three U.S. children's hospitals evaluating the impact of a multifaceted stewardship intervention including consensus guidelines, education, and group level audit and feedback on reducing empiric vancomycin use. The primary outcomes were (1) vancomycin administration within 12 hours of suspected SBI onset and (2) empiric vancomycin days of therapy (DOT) during the first 3 days after suspected SBI onset. Secondary outcomes included overall vancomycin DOT/1000 patient days; organ dysfunction at days 3 and 7; 14-day mortality; and invasive MRSA infection not covered empirically. Empiric vancomycin use was modeled using mixed-effects logistic regression and vancomycin DOT was modeled using mixed effects Poisson regression. RESULTS: Among 4,549 episodes targeted by the intervention, there was an immediate reduction in empiric vancomycin use after the intervention (OR 0.71, 95% CI 0.54-0.95, P=0.02), with no significant change in post-intervention slope. Empiric vancomycin days after suspected SBI onset decreased by 24% immediately after the intervention (IRR 0.76, 95% CI 0.65-0.89, P<0.01), with no significant change in postintervention slope. There were no increases in mortality, organ dysfunction, or missed MRSA infections postintervention. CONCLUSION: A multifaceted stewardship intervention reduced empiric vancomycin without evidence of harm, supporting the safety and feasibility of targeting empiric antibiotic prescribing in the PICU setting.
引用
- Chiotos K, Jaggi P, Facer EE, et al. Reducing Empiric Vancomycin Use in the Pediatric Intensive Care Unit: a Multicenter Study. Clin Infect Dis. 2026. PMID: 42700377. doi:10.1093/cid/ciag545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。